SCHÓLARENA SCHÓLARENA

**EDITORIAL** 

# Antibiotic Resistance Involves Antimicrobial Inactivation in Global Communities

Martins IJ<sup>1,2,3\*</sup>

<sup>1</sup>Centre of Excellence in Alzheimer's disease Research and Care, Sarich Neuroscience Research Institute, Edith Cowan University, Verdun Street, Nedlands, Western Australia, Australia <sup>2</sup>School of Psychiatry and Clinical Neurosciences, The University of Western Australia, Nedlands <sup>3</sup>McCusker Alzheimer's Research Foundation, Hollywood Medical Centre, 85 Monash Avenue, Suite 22, Nedlands, Australia


\***Corresponding author:** Martins IJ, School of Medical Sciences, Edith Cowan University, Western Australia 6009, Australia, Tel: +6186.304.2574, E-mail: i.martins@ecu.edu.au

**Citation:** Martins IJ (2017) Antibiotic Resistance Involves Antimicrobial Inactivation in Global Communities. SAJ Pharma Pharmacol 2: 102

#### Editorial

The science of ageing has become of critical interest to the antimicrobial drug industry with aging and geriatric medicine associated with antibiotic resistance and mitochondrial apoptosis with relevance to the global chronic disease epidemic. In the United States and Europe the geriatric population (> 65 years) is expected to double by the year 2060 with the death rate in the European Union in the geriatric population to be greater than 80% when compared with individuals <65 years [1]. Antimicrobial resistance has led to increased medical costs with the emergence of new antibiotic resistant infections in the United States and other countries [2-10]. The worldwide overuse of antimicrobial drugs and lack of new antibiotic agents has led to a major problem with healthcare in various diabetic and geriatric communities. Antibiotic resistance has led to assessment of preventive strategies associated with newer drug development to assist clinicians in the treatment of diabetics, geriatrics and Alzheimer's disease individuals [2-10].

Genomic information has become important to antibiotic resistance and genomic medicine is now important as a preventative strategy to increase antibiotic treatment in aging and geriatric individuals (Figure 1). In diabetic individuals the inability to control plasma glucose levels has been associated with inappropriate antibiotic use relevant to poor glycemic control and the treatment of antibiotic-resistant infections [5]. In aging and Alzheimer's disease the amyloid beta peptide has become of critical interest to antimicrobial drugs with its therapeutic role as a natural antibiotic [11,12]. The connections between glucose dyshomeostasis and amyloid beta aggregation has been documented in cells from obese and Alzheimer's disease individuals [13-15]. Novel genomic information now indicates that the gene Sirtuin 1 (Sirt 1) that regulates the suprachiasmatic nucleus is important to plasma glucose and amyloid beta metabolism with Sirt 1 inactivation connected to the inappropriate hepatic amyloid beta, glucose, drug metabolism associated with drug-drug interactions and inactivation of antimicrobial therapy (Figure 1) [16-22].



**Figure 1:** Nutritional therapy is essential for maintenance of Sirtuin 1 (Sirt 1) regulation of glucose, amyloid beta and nitric oxide metabolism. Sirt 1 inactivation is associated with mitophagy and inactivation of hepatic antimicrobial drug metabolism. In diabetes, geriatrics and Alzheimer's disease individuals Sirt 1 regulation is essential to maintain antibiotic use with Sirt 1 inhibitors such as LPS that induces magnesium and zinc deficiency connected to antimicrobial inactivation in these individuals

The diabetes severity index is now related to the inactivation of Sirt 1 with Sirt 1 relevant to senescence in diabetes, geriatrics and Alzheimer's disease [23]. Sirt 1 and its antimicrobial properties involve nitric oxide (NO) with Sirt 1 inactivation involved with NO dyshomeostasis and mitophagy. The use of antibiotics in aging and diabetes may require NO homeostasis and an intact immune system with Sirt 1 inactivation in aging, diabetes and AD associated with antibiotic resistance relevant to toxic immune reactions and mitophagy connected to global chronic disease (Figure 1) [20,24]. The gene Sirt 1 and its repression is regulated by the bacterial lipopolysaccharide (LPS) that are released from Gram negative bacteria [25]. LPS is critical to glucose dyshomeostasis and amyloid beta aggregation with elevated plasma LPS levels associated with non alcoholic fatty liver disease relevant to inactivation of antimicrobial drug therapy [18-21,25,26]. Antimicrobial drug therapy is associated with bacterial amyloid peptide induced amyloid beta aggregation [27,28].

Nutritional therapy is essential for antimicrobial activation and the therapeutic use of antibiotics. Diet that regulate NO are essential to prevent antimicrobial drug inactivation [29]. Low fat diets that do not allow LPS absorption are essential to prevent inactivation of antimicrobial use [30]. Sirt 1 inhibitors such as suramin and sirtinol should be carefully regulated to prevent complete Sirt 1 inactivation [31]. Caffeine as an antimicrobial/Sirt 1 modulator and various Sirt 1 activators should be consumed to prevent antibiotic resistance. LPS and its effects on magnesium and zinc deficiency should be carefully assessed to prevent antimicrobial drug inactivation and mitophagy [20,31-34].

# Acknowledgement

This work was supported by grants from Edith Cowan University, the McCusker Alzheimer's Research Foundation and the National Health and Medical Research Council.

### Conclusion

The major interest in genomic medicine in healthcare in various communities with relevance to antibiotic resistance has led to early plasma Sirt 1 analysis as an assessment for preventive strategies associated with continued therapeutic antibiotic use with relevance to genomic medicine development in aging, diabetes and Alzheimer's disease. Nutritional therapy is essential to maintain antimicrobial activation with relevance to mitophagy and the global chronic disease epidemic.

## References

1. Martins IJ (2017) Biomarker Tests and Ageing Science. Ageing Sci Ment Health Stud 1: 1-2.

2. Yoshikawa TT (2002) Antimicrobial resistance and aging: beginning of the end of the antibiotic era? J Am Geriatr Soc 50: 226-9.

3. Beckett Cl, Harbarth S, Huttner B (2015) Special considerations of antibiotic prescription in the geriatric population Clin Microbiol Infect 21: 3-9.

4. Xavier W, Sukumaran MT, Varma AK, Kumar H, Chellan G (2014) Emergence of multi drug resistant bacteria in diabetic patients with lower limb wounds. Indian J Med Res 140: 435-7.

5. Boyanova L, Mitov I (2013) Antibiotic resistance rates in causative agents of infections in diabetic patients: rising concerns. Expert Rev Anti Infect Ther 11: 411-20.

6. Arvanitis M, Anagnostou T, Kourkoumpetis TK, Ziakas PD, Desalermos A, et al. (2014) The Impact of Antimicrobial Resistance and Aging in VAP Outcomes: Experience from a Large Tertiary Care Center. PLoS One 9: e89984.

7. Beckett CK, Harbarth S, Huttner B (2015) Special considerations of antibiotic prescription in the geriatric population. Clin Microbiol Infect 21: 3-9

8. Ventola CL (2015) The Antibiotic Resistance Crisis. Part 1: Causes and Threats PT 40: 277-83.

9. WHO (2017) Antimicrobial resistance. Geneva, Switzerland.

10. Public and International Health (2016) Antimicrobial Resistance Empirical and Statistical Evidence-Base-A report from the Department of Health Antimicrobial Resistance Strategy Analytical Working Group.

11. Kumar DK, Eimer WA, Tanzi RE, Moir RD (2016) Alzheimer's disease: the potential therapeutic role of the natural antibiotic amyloid-β peptide. Neurodegener Dis Manag 6: 345-8.

12. Soscia SJ, Kirby JE, Washicosky KJ, Tucker SM, Ingelsson M, et al. (2010) The Alzheimer's Disease-Associated Amyloid β-Protein Is an Antimicrobial Peptide. PLoS One 5: e9505.

13. Boyt AA, Taddei TK, Hallmayer J, Helmerhorst E, Gandy SE, et al. (2000) The effect of insulin and glucose on the plasma concentration of Alzheimer's amyloid precursor protein. Neuroscience 95: 727-34.

14. Tharp WG, Gupta D, Smith J, Jones KP, Jones AM, et al. (2016) Effects of glucose and insulin on secretion of amyloid-β by human adipose tissue cells. Obesity 24: 1471-9.

15. Furst AJ, Lal RA (2011) Amyloid- $\beta$  and glucose metabolism in Alzheimer's disease. J Alzheimers Dis 26: 105-16.

16. Martins IJ (2016) Type 3 Diabetes with links to NAFLD and Other Chronic Diseases in the Western World. Int J Diabetes Metab Disord 1: 1-5.

17. Martins IJ (2017) Calorie Sensitive Anti-Aging Gene Regulates Hepatic Amyloid Beta Clearance in Diabetes and Neurodegenerative Diseases. EC Nutr ECO 1: 30-2.bial Resistance Strategy Analytical Working Group.

18. Martins IJ (2017) Inactivation of Anti-Aging Genes is related to Defective Drug Metabolism in Diabetes. Int J Drug Disc 1: 3.

19. Martins IJ (2016) Drug Therapy for Obesity with Anti-Aging Genes Modification. Ann Obes Disord 1: 1001.

20. Martins IJ (2017) Antimicrobial activity inactivation and toxic immune reactions induce Epilepsy in human. J Med Discov 2: 1-7.

21. Martins IJ (2017) Heat Shock Gene Dysregulation and Inactivation of Drug Therapy. EC Pharmacol Toxicol 1: 13-5.

22. Martins IJ (2017) Drug-Drug Interactions with Relevance to Drug Induced Mitochondrial Toxicity and Accelerated Global Chronic Diseases. EC Pharmacol Toxicol 3: 18-21.

23. Martins IJ (2017) Insulin Therapy Inactivation is connected to NAFLD and Diabetes Severity Index. J Diab Clin Stud 1: 1-3.

24. Korzeniowski OM (1989) Effects of antibiotics on the mammalian immune system. Infect Dis Clin North Am 3: 469-78.

25. Martins IJ (2017) The Future of Genomic Medicine Involves the Maintenance of Sirtuin 1 in Global Populations. Int J Mol Biol 2: 1-4.

26. Martins IJ (2016) Bacterial Lipopolysaccharides Change Membrane Fluidity with Relevance to Phospholipid and Amyloid Beta Dynamics in Alzheimer 's Disease. J Microb Biochem Technol 8: 322-24.

27. Martins IJ (2017) Antimicrobial Drugs and Bacterial Amyloid Peptide Induce Toxic Manifestations in Chronic Diseases. EC Pharmacol Toxicol ECPT-17-ED-154.

28. Martins IJ (2015) Unhealthy Diets Determine Benign or Toxic Amyloid Beta States and Promote Brain Amyloid Beta Aggregation. Austin J Clin Neurol 2: 1060-6.

29. Martins IJ (2015) Nutritional diets accelerate amyloid beta metabolism and prevent the induction of chronic diseases and Alzheimer's disease. Photon ebooks. J Endocrinol Metabol 1-48.

30. Martins IJ (2015) Overnutrition Determines LPS Regulation of Mycotoxin Induced Neurotoxicity in Neurodegenerative Diseases. Int J Mol Sci 16: 29554-73.

31. Martins IJ (2017) Nutrition Therapy Regulates Caffeine Metabolism with Relevance to NAFLD and Induction of Type 3 Diabetes. J Diabetes Metab Disord 4: 019.

32. Khan F, Patoare Y, Karim P, Rayhan I, Quadir MA, et al. (2005) Effect of magnesium and zinc on antimicrobial activities of some antibiotics. Pak J Pharm Sci 18: 57-61.

33. Martins IJ (2016) Magnesium Therapy Prevents Senescence with the Reversal of Diabetes and Alzheimer's Disease. Health 8: 694-710.

34. Martins IJ (2017) Magnesium deficiency and induction of NAFLD and Type 3 diabetes in Australasia. AMJ 10: 235-7.